New drug approvals for 2020: Synthesis and clinical applications

被引：37
|
作者：
Yuan, Shuo [1 ,2 ]
Luo, Yong-Qiang [1 ,2 ]
Zuo, Jia-Hui [1 ,2 ]
Liu, Hui [1 ,2 ]
Li, Fang [1 ,2 ]
Yu, Bin [1 ,2 ]
机构：
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou 450001, Peoples R China
[2] Zhengzhou Univ, Key Lab Adv Drug Preparat Technol, Mil Educ, Zhengzhou 450001, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 215卷
基金：
中国国家自然科学基金;
关键词：
New drugs; Chemical synthesis; Clinical applications; FARNESYL-PROTEIN TRANSFERASE; PEPTIDE CGRP; OPEN-LABEL; PHASE-III; DISCOVERY; INHIBITORS; EFFICACY; POTENT; SELPERCATINIB; MULTICENTER;
D O I：
10.1016/j.ejmech.2021.113284
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
53 New drugs including 38 chemical entities and 15 biologics were approved by the U.S. Food and Drug Administration during 2020. Among the marketed drugs, 34 new small molecule drugs and 4 new diagnostic agents with privileged structures and novel clinical applications represent as promising leads for the development of new drugs with the similar indications and improved therapeutic efficacy. This review is mainly focused on the clinical applications and synthetic methods of 34 small-molecule drugs newly approved by the FDA in 2020. (c) 2021 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：34
相关论文
共 50 条
12345